NCT02274545View on ClinicalTrials.gov

Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

May 31, 2016

Conditions
Influenza A Virus, H7N9 Subtype
Interventions
BIOLOGICAL

H7N9 Anhui 2013/AA ca

10\^7.0 fluorescent focus units (FFU); 0.5 mL of vaccine will be delivered as a nasal spray by an Accuspray device (0.25 mL per nostril)

BIOLOGICAL

Inactivated subvirion H7N9 vaccine

30 mcg

Trial Locations (1)

14642

University of Rochester Medical Center, Rochester

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02274545 - Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old | Biotech Hunter | Biotech Hunter